Truist Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $169

Benzinga · 4d ago
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $172 to $169.